Quality: 5/75

jcs

JCS: SaaS Turnaround Story - Switching Costs Can't Switch Off Losses

Updated 24 Oct 2025

Challenging turnaround play with fair value -$0.022 vs current $0.050. Persistent losses, 5% churn, narrow moat. High risk, negative outlook.

View note

eye

EYE: MIGS Pioneer - Breakeven or Bust in the Canal Zone

Updated 8 Oct 2025

Nova Eye Medical: BUY rating, A$0.48 fair value vs A$0.14 current price (243% upside). Pre-profit MIGS specialist targeting H1FY26 breakeven with 25% revenue growth.

View note